<DOC>
	<DOCNO>NCT02277847</DOCNO>
	<brief_summary>Study Design : Treatment , Randomized , Open Label , Parallel Assignment This study open randomize control trial aim assess efficacy safety Idarubicin ( IDA ) different dose 8mg/m2 10mg/m2 combined cytarabine induction therapy newly diagnose Acute Myeloid Leukaemia ( AML ) . All recruit patient allocate group A ( 8mg/m2 group ) group B ( 10mg/m2 ) random . It advise induction therapy begain late 3 day randomization . The regimen detail refer therapy protocol .</brief_summary>
	<brief_title>Idarubicin Different Dosages Induction Therapy Newly Diagnosed Acute Myeloid Leukaemia</brief_title>
	<detailed_description>Idarubicin new generation anthracyclines high lipophilicity permeable cytomembrane therefore cytotoxic leukemic cell . It pass blood brain barrier easily . IDA advantage anthracyclines prolong overall survival AML . The induction therapy idarubicin cytarabine first-line induction regimen AML . Many clinical trail indicate dosage IDA positively correlate effectiveness . But China IDA use varied dosage range 6 12 mg/m2 . In Chinese hospital , usual dosage range IDA 6 8 mg/m2 may contribute much low 5-year survival rate AML report Chinese medical literature foreign literature . What suitable dosage IDA induction therapy Chinese AML population best efficacy l increase side effect ? Till retrospective , randomize multicentered clinical trail answer question remission-inducing dosage IDA . All exist trial till small- sample , single-centered , retrospective non-randomized provide strong evidence . This study aim compare two induction dose 8mg/m2 10mg/m2 IDA method prospective randomize multi-centered trial.The two dos IDA use many Chinese hospital many year , effectiveness safety recognize . This trail aim side effect IDA induction therapy effect long-term survival Chinese AML population , provide strong evidence optimal dosage IDA Chinese AML population.It reduce waste medical social resource also produce good social economic benefit .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Age : 14~60 year old ; gender limit . Diagnosis : accord diagnosis standard AML ( exception M3 ) ( accord 2008 WHO diagnosis criterion AML ) . Performance status bad Eastern Cooperative Oncology Group ( ECOG ) score â‰¤3 . Research subject must sign informed consent document . Chronic myelogenous leukemia ( CML ) crisis phase . AML transform myeloproliferative disease . Be accompany progress neoplasm . With severe malfunction liver , lung , kidney heart : plasma level direct bilirubin , indirect bilirubin , alanine transaminase , aspartate transaminase serum creatinine 2 time higher normal , cardiac function grade II . With severe infection .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Idarubicin</keyword>
	<keyword>Cytosine arabinoside</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>